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Recombinant human erythropoietin (rHuEPO) is used as doping a substance. Anti‐
doping efforts include urine and blood testing and monitoring the athlete biological
passport (ABP). As data on the performance of these methods are incomplete, this
study aimed to evaluate the performance of two common urine assays and the
ABP. In a randomized, double‐blinded, placebo‐controlled trial, 48 trained cyclists
received a mean dose of 6000 IU rHuEPO (epoetin β) or placebo by weekly injection
for eight weeks. Seven timed urine and blood samples were collected per subject.
Urine samples were analyzed by sarcosyl‐PAGE and isoelectric focusing methods in
the accredited DoCoLab in Ghent. A selection of samples, including any with false
presumptive findings, underwent a second sarcosyl‐PAGE confirmation analysis.
Hematological parameters were used to construct a module similar to the ABP and
analyzed by two evaluators from an Athlete Passport Management Unit. Sensitivity
of the sarcosyl‐PAGE and isoelectric focusing assays for the detection of erythropoi-
etin abuse were 63.8% and 58.6%, respectively, with a false presumptive finding rate
of 4.3% and 6%. None of the false presumptive findings tested positive in the confir-
mation analysis. Sensitivity was highest between 2 and 6 days after dosing, and
dropped rapidly outside this window. Sensitivity of the ABP was 91.3%. Specificity
of the urine assays was high; however, the detection window of rHuEPO was narrow,
leading to questionable sensitivity. The ABP, integrating longitudinal data, is more
sensitive, but there are still subjects that evade detection. Combining these methods
might improve performance, but will not resolve all observed shortcomings.
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HEUBERGER ET AL. 12911 | INTRODUCTION
Athletes have used drugs to enhance sports performance throughout
history, despite all efforts to ban these doping substances. To detect
cheating athletes, the World Anti‐Doping Agency (WADA) oversees
a global doping control system using blood and urine samples that
are collected both in competition and out of competition. If an athlete
is tested positive, this will usually lead to a suspension of two or four
years, depending on the substance found and the circumstances of the
case. It can be up to lifetime ineligibility for recidivists.1 One substance
that is widely abused, especially in endurance sports, is recombinant
human erythropoietin (rHuEPO). rHuEPO has shown to positively
affect maximal performance,2,3 and although there is a lack of clear
scientific proof whether it also improves actual endurance perfor-
mance,4 the belief in erythropoietin's effects on performance among
athletes, their staff and the general public is overwhelming. Recent
confessions to rHuEPO misuse by many cyclists from the 1990–
2010 era, including former champions like Lance Armstrong, unfolded
an rHuEPO epidemic, at least within cycling. Testing for rHuEPO use
was introduced in 2000, and results from the testing figures published
by WADA seem to indicate that rHuEPO is still used by athletes.5 In
the period 2012–2017,5 a total of 200 451 urine samples were tested
for presence of erythropoiesis stimulating agents (ESAs) and 305 sam-
ples (0.15%) produced adverse analytical findings (AAFs). In addition,
12 966 blood samples were tested, of which 61 samples (0.44%) pro-
duced AAFs. These AAFs are interpreted as proof an athlete used an
ESA. In addition to these specific tests for rHuEPO, WADA introduced
the athlete biological passport (ABP) in 2009, in which several bio-
markers of an individual are measured longitudinally. The hematologi-
cal module containing hematological markers is applied to monitor use
of erythropoiesis stimulating agents such as rHuEPO. Abnormalities in
these markers can be used to start targeted testing in that individual,
or even as a doping violation by itself.
Although doping tests are intended to discourage athletes from
using doping, detect the ones that are violating doping rules, and protect
the athletes that play fair, their ability to do so completely depends on
the performance of the tests and an intelligent testing program
collecting samples within the window of detection. Technical docu-
ments describing the urine assays for detecting ESA use are available
through WADA6 and articles on the methods have been published.7-11
Some information on detection windows for isoelectric focusing (IEF)
and sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS‐
PAGE) is available for several rHuEPO variants from open label stud-
ies.12-14 However, well‐designed blinded studies describing the critical
assay characteristics of sensitivity and specificity and the detectionwin-
dow, are not sufficiently (publicly) available.15We believe that scientific
evidence underpinning internationally and widely applied doping tests
should be available in order to understand the value of the tests, protect
fair‐playing athletes, and collaborate on improving doping detection.
For that reason, we aimed to evaluate the performance of three main
methods being used in rHuEPO detection by determining sensitivity
and specificity of the sarcosyl‐PAGE and IEF assays on urine samples,
and of the ABP and its hematological module.2 | METHODS
2.1 | Study design and participants
For the purpose of this study, blood and urine samples were used that
were obtained in a double‐blind, randomized, placebo‐controlled, par-
allel, single‐center study on rHuEPO, in which 48 healthy male cyclists
between 18 and 50 years of age were included. The design of this trial
was described elsewhere.4 In short, the main inclusion criteria were
maximum power‐to‐weight ratio during the maximal exercise test at
screening exceeding 4 W/kg, Hb between 8.0 and 9.8 mmol/L (equiv-
alent to 12.8–15.7 g/dL) and Ht below 48% at screening and not being
subject to anti‐doping regulation or using medication that could
potentially interact with the study drugs or study assessments. All par-
ticipants gave written informed consent prior to any study‐related
activity. The study was approved by the Independent Ethics Commit-
tee of the Foundation ‘Evaluation of Ethics in Biomedical Research’
(Stichting Beoordeling Ethiek Biomedisch Onderzoek), Assen, Nether-
lands. The study is registered in the Dutch Trial Registry (Nederlands
Trial Register, NTR) under study number NTR5643.2.2 | Randomization and masking
Randomization to the rHuEPO or the placebo group (1:1) was done by
a randomization code generated by an unblinded statistician who was
otherwise not involved in the execution of the study. Enrolment of
subjects was performed by a blinded study physician.3 | PROCEDURES
3.1 | Treatment
Epoetin β (NeoRecormon, Roche, Basel, Switzerland), prepared from
multidose vials containing a lyophilizate of 50 000 IU epoetin β and
10 mL solvent for solution for injection, or saline (0.9% NaCl) was
administered subcutaneously with weekly abdominal injections for
8 weeks. Dosing aimed to reach a target Hb of 10%–15% increase
compared to the baseline Hb value, similar to previous studies investi-
gating effects of rHuEPO on performance.16 The first four injections
contained 5000 IU per injection. The dose was modulated by an
unblinded, non‐study‐related physician to 6000 IU, 8000 IU, or 10
000 IU in the final four weeks in case the Hb level was below the tar-
get range, doses similar to known practices in professional cycling.17
When the Hb was in the target range, 2000 IU was administered. If
the Ht was equal to or exceeded 52% or if the Hb exceeded the upper
limit of the Hb range (increase of 15% compared to baseline), a pla-
cebo injection was administered.
All participants also received open‐label daily oral doses of 200 mg
ferrous fumarate and 50 mg ascorbic acid (both Pharmachemie B.V.,
Haarlem, Netherlands).
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Urine samples were collected for each subject and 50 mL was stored in
Falcon tubes (Greiner Bio‐One International GmbH, Kremsmuenster,
Austria) at −70°C. Samples were collected at approximately 1 hour,
2 days, 4 days, and 7 days after the second dose and at approximately
12 days after the last dose. These samples were taken while subjects
had not exercised in the preceding hours. To evaluate potential effects
of exercise on the outcome of the test, a sample was taken as soon as
the subject could urinate after the maximal exercise at approximately
4 days after the second dose and after a race to the top of Mont
Ventoux at approximately 12 days after the last dose. Samples were
shipped to the WADA‐accredited anti‐doping laboratory DoCoLab
UGent by courier in two separate batches. The lab was aware these
samples were research samples, but was blinded to the administered
treatment.
All hematology samples were drawn after participants were
seated with their feet on the floor for at least 10 minutes, at the fol-
lowing time points: 1–6 weeks before the first dose; directly before
the first, third, fifth and seventh doses; approximately 12 days and
4 weeks after the last dose. In general, this means there were
2 weeks between two samples. Samples were analyzed within
2 hours at the Leiden University Medical Centre (LUMC) on a
Sysmex XN9000 analyzer (Sysmex Corporation, Kobe, Japan). Sam-
ples taken at the Mont Ventoux race were split into two aliquots,
one of which was kept at room temperature for determination of
leucocytes and leucocytes differentiation and one was kept between
2 and 8°C for determination of hemoglobin, hematocrit, erythro-
cytes, reticulocytes, MCV, MCH, MCHC, thrombocytes, immature
reticulocyte fraction (IRF), and red blood cell distribution width
(RDW‐SD). Samples were driven by courier to the LUMC and analy-
sis took place within 36 hours of collection.3.3 | Sarcosyl‐PAGE urine assay
The sarcosyl‐PAGE urine assay was used as described in the WADA
technical document.6 In short, immunopurification of the sample was
performed with antibodies other than the one used for immunoblot-
ting before loading 15 μL of sample on pre‐cast polyacrylamide gels
(NuPAGE BisTris gels, 10% T, 1.5 mm, as described previously18), with
15 slots for test samples per gel (performance conditions: I = 1.56 mA/
cm2 at 0.16A; time = 45 minutes). For purification, Stemcell ELISA was
used as described previously, with 15 μL SAR buffer.11
In addition, a negative control sample, a positive control sample
containing rHuEPO, and a reference to enable to define apparent
molecular mass were run in separate slots. Running buffer used was
sodium N‐lauroyl sarcosinate, and after the electrophoretic separation
double‐blotting was performed with the monoclonal mouse anti‐
human EPO antibody clone AE7A5 and a secondary antibody. The
secondary antibody was a goat anti‐mouse biotinylated polyclonal
antibody IgG (H + L), cross‐adsorbed, HRP (Thermo Scientific product
no. 31432) and used in combination with a streptavidin horseradishperoxidase complex (Biospa, Milan, Italy) and a substrate (SuperSignal
West Femto Maximum Sensitivity; Thermo Scientific, Waltham, MA,
USA). The electrophoretic patterns of ESAs were revealed by the
use of an amplified chemiluminescent system. Detection of exogenous
EPO, in this case epoetin β, was done on the basis of the characteristic
band shape (“broad band”) and different (higher) apparent molecular
mass than endogenous EPO. A sample was termed positive if a single
band was visible above the negative control EPO, or if a mixed band
both at the endogenous and exogenous location or a diffuse or faint
area of the band above the corresponding endogenous band were vis-
ible, as per the WADA technical document.63.4 | Isoelectric focusing urine assay
The IEF urine assay was used as described in the WADA technical
document.6 In short, immunopurification of the sample was performed
with antibodies other than the one used for immunoblotting before
loading 20 μL of sample on the gel, with 30 slots for test samples
per gel. For purification, Stemcell ELISA was used as described previ-
ously, elution with 30 μL 4.4% CHAPS.19 IEF was performed in a pH
range compatible with the isoelectric points (pI) of both the natural
EPO and its recombinant analogues. IEF was performed under dena-
turing conditions (approximately 7 M urea). After the electrophoretic
separation double‐blotting was performed with the monoclonal mouse
anti‐human EPO antibody clone AE7A5 and a secondary antibody.
The secondary antibody was a goat anti‐mouse biotinylated polyclonal
antibody IgG (H + L), cross‐adsorbed, HRP (Thermo Scientific product
no. 31432) and used in combination with a streptavidin horseradish
peroxidase complex (Biospa, Milan, Italy) and a substrate (SuperSignal
West Femto Maximum Sensitivity; Thermo Scientific, Waltham, MA,
USA). The electrophoretic patterns of ESAs were revealed by the
use of an amplified chemiluminescent system. Detection of exogenous
EPO, in this case epoetin β, was done on the basis of the relative loca-
tion of the bands compared to the position of the bands correspond-
ing to the rHuEPO biological reference preparation (BRP) of the
European Pharmacopeia (equimolar mixture of epoetin‐alfa and ‐β),
which define the basic and acidic areas. A sample was termed positive
if there were at least three acceptable, consecutive bands in the basic
area, and if the two most intense bands measured by densitometry
were in the basic area, as per the WADA technical document.6 It
should be noted that the IEF assay is currently not used in routine
practice by the DoCoLab and therefore the associated analyses are
exploratory.3.5 | Urine sample evaluation (screening)
Samples were designated as screening negative, screening positive or
non‐detectable by the DoCoLab in Ghent. Samples were non‐
detectable if no band was detected in the EPO (endogenous or exog-
enous) designated region.
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After results of the screening analysis were available, the outcome was
analyzed by unblinded Centre for Human Drug Research (CHDR)
researchers. The WADA procedure describes that samples returning
suspicious results at this screening stage are termed “presumptive
adverse analytical findings”, and need to undergo confirmation in a
confirmation procedure.20 In the current study, slightly different ter-
minology was used to differentiate between suspicious results from
a subject treated with rHuEPO or with a placebo. Therefore, samples
from placebo‐treated subjects that generated a suspicious result in
the screening analysis were termed “false presumptive findings”. For
the sarcosyl‐PAGE assay these were re‐analyzed with a confirmatory
sarcosyl‐PAGE assay. Both the initial and the confirmation methodol-
ogy were the same. In order to keep this confirmation analysis blinded
to the DoCoLab, true positive, true negative, and false negative sam-
ples were included as well, and this selection of samples was relabeled
by CHDR staff for analysis. Samples were only deemed positive, sim-
ilar to routine analysis, when they would be forwarded for a manda-
tory second opinion. The WADA technical document requires6 that
all presumptive adverse analytical findings are evaluated by a recog-
nized expert. After evaluation by the laboratory performing the analy-
sis, samples are therefore forwarded to a WADA‐recognized expert.
Currently, these experts are co‐authors of the WADA technical docu-
ment6 and have extensive scientific knowledge of ESAs, their detec-
tion methodology and potential issues in the detection of ESAs. In
the framework of this study, samples were not subjected to a second
opinion and the interpretation was solely based on the laboratory
performing the analysis. No WADA‐recognized expert as per the tech-
nical document6 was involved. In case of doubt, samples were deemed
negative.3.7 | Osmolality
Osmolality was determined by taking an aliquot from the homoge-
nized, centrifuged samples, using the freezing point method on an
Osmometer Auto & Stat, OM‐6050 (Arkray, Kyoto, Japan). Osmolality
determination was initiated after all analyses had been performed to
provide insights into potential effects of osmolality on assay results.3.8 | Athlete biological passport
A method similar to the adaptive model of the ABP was constructed
internally using Microsoft Excel 2013 (Redmond, WA, USA), as the
official WADA software was not made available for this study. Individ-
ual curves of each separate hematological parameter from blood sam-
ples were produced by plotting the observed value, and the 99.7%
confidence interval (CI) around that value. For the first measurement,
the 99.7% CI was based on the population mean (Pop. mean) ± 3xSD
of all available data points from the screening and baseline hematolog-
ical samples of all subjects that completed these visits (Pop. SD); for
IRF and RDW‐SD only the value at baseline was used as they werenot determined at screening. For following data points, with each
additional available measurement the 99.7% CI was based more on
individual data, and calculated as follows:
• second data point:
Pop:meanþ individual value 1ð Þ
2
± SD Pop:meanþ individual value 1½  þ 2*Pop:SD
• third data point:
Pop:meanþ individual value 1 and 2ð Þ
3
± 2*SD Pop:meanþ individual value 1 and 2½  þ Pop:SD
• fourth data point:
Pop:meanþ individual value 1;2 and 3ð Þ
4
± 3*SD Pop:meanþ individual value 1;2 and 3½ 
• fifth data point:
Pop:meanþ individual value 1;2;3 and 4ð Þ
5
± 3*SD Pop:meanþ individual value 1;2;3 and 4½ 
• etc.
The OFF score (OFFS) was calculated using the following formula:
([hemoglobin concentration in g/dL]) * 10 ‐ (60 * √([Reticulocyte per-
centage])). Graphs of each separate variable belonging to one subject
were combined into one document and sent with a coded (blinded)
identifier to the DoCoLab in Ghent for evaluation of a subject being
negative, suspicious or positive. Two independent researchers at the
DoCoLab, which is designated as an Athlete Passport Management
Unit (APMU) by WADA, independently evaluated the data and two
sets of results were generated and analyzed, so that reproducibility
could also be evaluated.3.9 | Exercise
Two urine samples per subject were collected after exercise: one after
a maximal exercise test to exhaustion at 4 days (±1 day) after the sec-
ond dose administration and one approximately 12 days after the last
dose after participants competitively completed an uphill road race
on the Mont Ventoux. This race was directly preceded by 110 km
cycling.
TABLE 1 Sarcosyl‐PAGE urine assay performance characteristics
(total N = 330)
Measure
Screening
Analysis
Screening
+Confirmation
Analysis
Value (%) Value (%)
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All data were stored in a clinical trial database (Promasys, Omnicomm
Inc., Fort Lauderdale, USA) and checked for accuracy and complete-
ness. A blinded data review was performed before code‐breaking
and analysis according to a standard procedure at our unit.Sensitivity 63.8 63.8
Specificity 95.7 100.0
False negative rate 36.2 36.2
False positive rate 4.3 0.0
Precision 93.1 100.0
False discovery rate 6.9 0.0
False omission rate 25.6 24.8
Negative predictive value 74.4 75.24 | STATISTICAL ANALYSIS
Standard assay characteristics were calculated based on the reported
results. For determining overall urine assay characteristics, only sam-
ples that were designated negative or positive were included in the
analysis. When determining sensitivity over time, two analyses were
done, one including and one excluding the samples designated non‐
detectable. For this analysis, samples were binned per day, and only
bins with more than one sample were included in the analysis. When
determining ABP assay characteristics, suspicious and positive were
combined as being an indication of rHuEPO use.5 | ROLE OF THE FUNDING SOURCE
This was an investigator initiated study by the foundation CHDR in
Leiden in collaboration with DoCoLab (Ghent, Belgium), Leiden Uni-
versity Medical Centre, the Anti‐Doping Authority of The Netherlands
and the Department of Pulmonary Diseases, VU University Medical
Centre, Amsterdam. There was no external funding source.6 | RESULTS
Forty‐nine participants were recruited. One participant withdrew after
the first dose administration and was replaced by a reserve participant,
whereas another participant withdrew after the fourth dose adminis-
tration. Both withdrawals were for personal reasons and not related
to the study treatment or medical concerns. All 48 subjects were
included in the urine detection analysis. Due to the incomplete ABP
profile of the withdrawn subject, 47 subjects were included in the
analyses for the ABP, of which 23 were in the rHuEPO group and
24 in the placebo group. All participants were living at sea level and
did not spend any substantial amount of time at (simulated) high
altitude.
Participants in the rHuEPO group received eight dosages of
epoetin β during the study. Mean rHuEPO dose was 5000 IU per
week during the first 4 weeks of the study and 7000 IU in the subse-
quent 4 weeks. On five occasions a placebo injection was intentionally
administered to subjects in the rHuEPO group, because of the mea-
sured hematocrit or hemoglobin levels. Of all 336 urine samples, 6
were not collected due to withdrawal from the study or subjects not
being able to perform the particular visit. One additional sample from
an rHuEPO treated subject was not analyzed with the IEF assay as it
was erroneously not included in the sample shipment at the time of
the IEF analysis.6.1 | Urine analysis6.2 | Sarcosyl‐PAGE urine assay
A total of 330 urine samples were analyzed for rHuEPO using
sarcosyl‐PAGE, of which 17 samples (5%) were termed non‐
detectable. Of these, 14 (82%) belonged to subjects in the rHuEPO
group and 3 (17%) to subjects in the placebo group. Based on the
remaining 313 samples, the sensitivity of sarcosyl‐PAGE after the
screening analysis was 63.5% and specificity was 95.7% (with seven
false presumptive findings; Table 1). These false presumptive findings
belonged to urine samples from six subjects.
Fourteen samples were analyzed for a second time in the confir-
mation analysis, including all seven samples producing a false pre-
sumptive finding in the screening analysis. All 14 samples were
correctly identified as negative in placebo subjects and positive for
rHuEPO subjects. The assay characteristics when taking both analyses
into account show specificity increased to 100% (Table 1).
When comparing samples that were collected before and directly
after a maximal exercise test on the same day, sensitivity was 100%
at 4 days, 92% and 100% at 5 days, 57% and 0% at 11 days, 33%
and 0% at 12 days, and 0% at 13 days since last dosing.6.3 | Sarcosyl‐PAGE sensitivity over time
When tested approximately 1–2 hours after the second rHuEPO dos-
ing (and 7 days after the first), 50% of rHuEPO treated subjects tested
positive (Figure 1). The sensitivity increased to approximately 81%
when urine was collected 2 days after the last dose, and was 95%–
100% between day 3 and 6 after the last dose. After 7 days, sensitivity
decreased again to approximately 50% and was 29% at 11 days, 18%
at 12 days, and 0% at 13 and 16 days after the last dose. When sam-
ples designated as non‐detectable are excluded, sensitivity slightly
increases, but is very similar.
FIGURE 1 Sarcosyl‐PAGE sensitivity versus time since dose. Sensitivity for the sarcosyl‐PAGE assay over time in the rHuEPO‐treated subjects.
The numbers at each data point represent the number of samples that are in a bin. A, includes samples that were designated non‐detectable; B,
excludes these samples.
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A total of 329 urine samples were analyzed for rHuEPO using IEF, of
which 68 samples (21%) could not be declared either positive or neg-
ative. Of these, 51 (75%) belonged to subjects in the rHuEPO group
and 17 (25%) to subject in the placebo group. Based on the remaining
261 samples, the sensitivity of IEF after a single analysis was 58.6%
and specificity was 94.0% (with 9 false presumptive findings;
Table 2). These false presumptive findings belonged to urine samples
from five subjects (one subject with three false presumptive samples
and two with two). There was no overlap with the false presumptive
findings in the sarcosyl‐PAGE assay. For IEF, no confirmation analysis
was performed. The focus of the urine analysis was on the sarcosyl‐
PAGE assay as that is the standard assay at the DoCoLab in Ghent,
whereas the IEF assay was only implemented for this study. For this
reason we decided not to perform a confirmation analysis for this
method. When comparing samples that were collected before and
directly after a maximal exercise test on the same day, sensitivity
was 50% and 89% at 4 days, 33% and 83% at 5 days, 42% and 0%
at 11 days, and 0% at for all samples at 12 and 13 days since last
dosing.TABLE 2 Isoelectric focusing urine assay performance characteris-
tics (total N = 329)
Measure Value (%)
Sensitivity 58.6
Specificity 94.0
False negative rate 41.4
False positive rate 6.0
Precision 87.8
False discovery rate 12.2
False omission rate 24.6
Negative predictive value 75.46.5 | Isoelectric focusing sensitivity over time
When tested approximately 1–2 hours after the second rHuEPO dos-
ing (and 7 days after the first), 42% of rHuEPO‐treated subjects tested
positive (Figure 2). The sensitivity increased to approximately 86%
when urine was collected 2 days after the last dose, and was 50%–
68% between days 3 and 5 after the last dose. After 6 and 7 days, sen-
sitivity decreased again to approximately 25 and 22% and was only
21% at 11 days and 0% at 12, 13, and 16 days after the last dose.
When samples designated as non‐detectable are excluded, sensitivity
increases significantly (Figure 2).
6.6 | Athlete biological passport
A total of 47 ABPs based on the collected blood samples were rated
for rHuEPO use by the two independent APMU staff members.
Results of the ABP performance by Evaluator 1 and Evaluator 2 are
depicted in Table 3. The sensitivity of the ABP by both evaluators
was 91.3% and specificity was 100% for Evaluator 1 and 95.8% for
Evaluator 2. Evaluator 1 classified 14 ABPs as positive, 7 as suspicious,
and 26 as negative. Evaluator 2 classified 15 ABPs as positive, 7 as sus-
picious and 25 as negative. Of all 47 ABPs, 39 were scored identically
by the evaluators. When the results for suspicious and positive were
combined, 44 ABPs were scored identically. One discrepancy between
evaluators was that Evaluator 2 designated an ABP of a placebo sub-
ject as suspicious, which was correctly designated as negative by Eval-
uator 1. Additionally, both evaluators designated a separate ABP as
negative while it belonged to a subject from the rHuEPO group. Inter-
estingly, the ABP from one rHuEPO‐treated subject was designated as
negative by both evaluators. This ABP, together with a true positive
and a true negative subject's ABP can be seen in Figure 3.7 | DISCUSSION
The present study evaluated the performance of current doping
detection methods for epoetin β (NeoRecormon) use by athletes.
FIGURE 2 Isoelectric focusing sensitivity versus time since dose. Sensitivity for the isoelectric focusing assay over time in the rHuEPO‐treated
subjects. The numbers at each data point represent the number of samples that are in a bin. A, includes samples that were designated non‐
detectable; B, excludes these samples.
TABLE 3 Athlete biological passport performance characteristics
(total N = 47)
Measure
Evaluator 1 Evaluator 2
Value (%) Value (%)
Sensitivity 91.3 91.3
Specificity 100.0 95.8
False negative rate 8.7 8.7
False positive rate 0.0 4.2
Precision 100.0 95.5
False discovery rate 0.0 4.5
False omission rate 7.7 8.0
Negative predictive value 92.3 92.0
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be highly sensitive for the applied dose of 5000 IU within a small time
range of 2−6 days after dosing. Of all non‐rHuEPO samples 4.3% was
labeled screening positive, but after the standard confirmation analysis
no false positives were found. Findings for IEF showed a slightly lower
sensitivity and slightly higher false presumptive finding rate of 6%.
Evaluation of the ABP based on hematology samples had high sensi-
tivity of 91.3% for rHuEPO use. Specificity was also high with 100%
and 95.8% for the two evaluators. However, this research brought for-
ward some concerns of all three methods.7.1 | Sarcosyl‐PAGE urine assay performance
The sarcosyl‐PAGE assay performed well 2−6 days after dosing, but
outside this window sensitivity falls rapidly. Given the long‐lasting
hematological effect of rHuEPO (red blood cell lifespan is around
120 days21), high frequency testing and intelligent testing strategies
(eg, targeted testing in combination with the ABP) are necessary to
attain a high probability to catch athletes abusing rHuEPO. A second
concern with this assay is that a small part of the samples (5%) were
non‐detectable, especially because this result occurred more often inrHuEPO treated subjects (83% of these samples). Non‐detectable
results in general have been associated with variety of reasons. Degra-
dation of EPO via neuraminidase activity, with consecutive loss of
sialic acid moieties will result in a shift in molecular weight of EPO
to lower molecular weight sections.22 Protease activity might lead to
the disappearance of EPO. Of course suppression of endogenous pro-
duction due to a negative feedback mechanism will also lower endog-
enous EPO levels, potentially below the limit of detection (LOD) of the
method. Finally, urine dilution could disturb the assay.23 With regard
to dilution however, only four samples with a non‐detectable result
(24% of all non‐detectable samples) were strongly diluted, having an
osmolality of <180 mOsm/kg (approximately corresponding to a spe-
cific gravity of <1.004,24 the applied cut‐off for not accepting a sample
in anti‐doping procedures). In contrast, 30 samples (10%) with similarly
low osmolality had positive or negative assay results. Therefore osmo-
lality (alone) does not seem to explain a non‐detectable result, and the
cause for such a result remains unclear. This finding also questions the
validity of the current process of rejecting samples based on specific
gravity when used in relation to testing for rHuEPO use. Of the 17
samples designated as non‐detectable for the sarcosyl‐PAGE assay,
13 had the same results in IEF, indicating the problem is probably sam-
ple related. Given that only three subjects had more than one sample
(namely two, and for one subject three) designated as non‐detectable,
this effect does not seem to be subject‐related. On top of this
unknown effect leading to non‐detectable results, athletes might
engage actively in manipulative behavior to prevent detection of
rHuEPO use. Implementing an additional immunoassay in the routine
doping procedure for non‐detectable samples evaluating if overall
erythropoietin levels are sufficiently present in such samples, would
therefore help interpret the result. If the overall erythropoietin levels
in the immunoassay are low or absent, the non‐detectable result could
be explained by low concentrations of erythropoietin (or no erythro-
poietin). If this is not the case, there might be a different cause for
the non‐detectable result that needs further attention. The analysis
could for example also show if there was a potential issue with recov-
ery, or cross‐reactivity with specific erythropoietin fragments due to
degradation.
FIGURE 3 Athlete biological passport graphs exemplary subjects. Six main panels of the Athlete Biological Passport of three exemplary subjects.
Black data points and the accompanying numbers are the values observed for this parameter in the particular subject. Grey points are the
calculated 99.7% CI of the (individual) normal values calculated as described in the text. A, subject that received placebo that was correctly
identified as not using rHuEPO. B, subject that received rHuEPO weekly for 8 weeks starting at time point 0 that was correctly identified as using
rHuEPO. C, subject that received rHuEPO weekly for 8 weeks starting time point 0 that was incorrectly identified as not using rHuEPO. OFFS:
Off‐score; IRF: Immature reticulocyte fraction.
HEUBERGER ET AL. 1297The aim of the screening procedure is to forward all potential pos-
itives and not to exclude any false negatives and in the confirmation
procedure, this ‘philosophy is reversed’; ie, not to report any false pos-
itives, as described previously. The sarcosyl‐PAGE assay partly does
allow for this at reasonable economically viable conditions with less
than 5% false presumptive findings forwarded to confirmation. What
is remarkable however, is that when the results from the same samplein the screening and confirmation analyses are compared, at least in
some cases these are clearly different (Figure 4). Sample preparation
errors (eg, sample swapping) cannot definitively be excluded as cause
of these discrepancies, but given that false presumptive findings were
observed in the screening analysis that was performed according to
the standard procedure for sample preparation as for official doping
samples, this seems unlikely. Furthermore, although no formal positive
FIGURE 4 Sarcosyl‐PAGE urine assay results of screening and confirmation analysis of false presumptive findings. Images of the sarcosyl‐PAGE
assay results taken from different gels with the nearest references (labeled ESA‐Mix) and the negative quality control (labeled NU) for each
relevant lane. Letters indicate the relevant lanes, with the matching upper‐case and lower‐case letters indicating the same sample. The orange line
indicates the level above which rHuEPO will stain. A, In lanes 10.39, 11.38, 12.37, and 17.33 urine samples taken from subjects receiving placebo
were analyzed and determined as suspect for rHuEPO use. In lanes 10.1009, 11.1008, 12.1007, and 17.1003 the same samples are analyzed in the
confirmation analysis. B, In lanes 12.193, 6.57, and 16.49 urine samples taken from subjects receiving placebo were analyzed and determined as
suspect for rHuEPO use. In lanes 3.1015, 6.1012, and 9.1010 the same samples were analyzed in the confirmation analysis. All indicated samples
in the screening analysis show staining above the orange line, which is what made them suspicious, with lanes 10.39, 11.38, and 12.37 even
staining a large portion above the orange line. This is not the case in the same samples in the secondary analysis (compare with lanes 10.1009,
11.1008, 12.1007).
1298 HEUBERGER ET AL.control samples were included in the confirmation analysis, authentic
positive samples from the study samples were among the samples
on all gels. In Figure 4 these are lanes 15.1005, 16.1004, 4.1014,
and 7.1011 of the confirmation analysis gels and 9.40, 15.35, and
13.192 of the screening analysis gels and these can therefore serve
as positive controls. Also, DTT and heating were used for all samples,
and these processing steps were performed at the same time for all
samples on a gel, making comparison between samples on one gel
valid. Finally, degradation was not checked as this is not required per
the WADA procedure for rHuEPO testing. However, such a factor
would not explain the false presumptive finding in the screening anal-
ysis. In the absence of a convincing alternative explanation for the
observed discrepancy in the outcome of the screening and confirma-
tion procedure, variability in assay performance needs to be consid-
ered as an explanation as well.
Finally, sensitivity of the assay did not seem to be affected by the
maximal exercise test. The race however did seem to impact sensitiv-
ity, with six subjects that tested positive at days 11 and 12 before the
race testing negative after the race. Of these six negative post‐race
samples, two were non‐detectable, potentially due to effects of the
exercise and hydration. The other four samples, however, were desig-
nated negative, indicating the race potentially affected the ability to
detect rHuEPO. These four subjects went from positive to negative
in approximately 8 hours, which is remarkable (Figure 5). One explana-
tion could be that the concentration of erythropoietin in the post‐race
samples was lower (possibly due to changes in urine concentration
during the race), and that the faint signal that was detected pre‐race
was therefore not visible post‐race.7.2 | Isoelectric focusing urine assay performance
Findings for the IEF assay were similar to the sarcosyl‐PAGE assay,
although overall sensitivity slightly worse for IEF, which is similar to
a previous study with micro‐doses of rHuEPO. The most striking dif-
ference between the two assays was a four‐fold higher incidence of
samples not being detectable for the IEF (21%). This could be due to
the fact that the IEF is not currently being used by the DoCoLab in
Ghent and was only implemented for this study, and less routine led
to more samples being designated as non‐detectable. Additionally, it
could be due to the effect of previously described neuraminidase
activity on IEF results. The LOD for sarcosyl‐PAGE as determined with
reference standards was the same as for IEF. Samples were stored fro-
zen immediately following collection until analysis. Samples were
defrosted overnight in a fridge and aliquoted immediately before anal-
ysis. While for sarcosyl‐PAGE, mostly protease activity will lead to
undetectable results and neuraminidase activity will lead to a shift
(lower molecular weight) of the rHuEPO band, we believe that neur-
aminidase activity might lead to complete “disappearance” of the
EPO bands in IEF and not in sarcosyl‐PAGE. This may contribute to
the observed difference. Similar to the worrying finding for sarcosyl‐
PAGE, the majority of the non‐detectable samples (75%) in IEF
belonged to rHuEPO‐treated subjects. This higher incidence in sam-
ples from doped athletes in both IEF and sarcosyl‐PAGE indicates that,
while the fact that no EPO can be detected at all is not a proof of dop-
ing, this information might be useful to plan target and/or follow up
tests as rHuEPO use might be associated with a non‐detectable result.
To rule out problems with the individual assay when such a result
FIGURE 5 Example of changes in sarcosyl‐
PAGE results during the race. Images of the
sarcosyl‐PAGE assay results taken from two
gels. In lanes 16.268 and 17.267, urine
samples taken pre‐race from two subjects
receiving rHuEPO were analyzed. In lanes
5.315 and 6.316, samples taken post‐race
from the same subjects were analyzed. Letters
indicate the relevant lanes, with A and a
indicating lanes from one subject, and B and b
from the other. Lanes labeled ESA‐Mix are
positive controls. Lanes labeled NU are
negative quality controls. The orange line
indicates the level where rHuEPO will stain. In
lanes 16.268 and 17.267, staining is clearly
present above the orange line, while this is not
the case in the samples from the same
subjects that were taken only approximately
8 hours later, after the race, in lanes 5.315 and
6.316.
HEUBERGER ET AL. 1299occurs, it could be useful to add a positive control to each sample, for
example using EPO from a different animal species, as is common for
most other doping analyses.
There was no overlap in false presumptive findings between the
sarcosyl‐PAGE and IEF assays, indicating that such a result is not
related to the sample.
In contrast to the sarcosyl‐PAGE assay, the maximal exercise test
potentially did have an effect on the assay result of the IEF assay.
Sensitivity was higher directly after the test compared to before.
For the race, however, we observed a similar outcome as for the
sarcosyl‐PAGE assay: three subjects tested positive before the race;
after the race two tested negative, and one non‐detectable. The
impairment in signal for these post‐race samples as observed in
the sarcosyl‐PAGE assay (Figure 5) was not observed in the IEF
assay for these two samples. However, this is solely based on
observed signal intensities and not on a quantitative observation.
As no internal standard was used, factors such as recovery differ-
ences in sample preparation between different batches/samples
might also have played a role. If there indeed was an effect ofexercise on the IEF test results, this effect was opposite for the race,
compared to the maximal exercise test.7.3 | Athlete biological passport performance
In addition to evaluating the urine assays, we constructed an ABP so
we could evaluate all tools used to detect rHuEPO use. This method
had a high sensitivity of 91.3%. Given that this data is collected longi-
tudinally and the method is less dependent on the time of sampling in
relation to dosing compared to the urine assay, this approach not sur-
prisingly has a better chance of detecting doping athletes. Neverthe-
less, almost 10% of subjects were not identified as suspicious or
positive based on their ABP. See as an example the false negative sub-
ject in Figure 3, whose variation in hematological parameters is actu-
ally very similar to that of the placebo subject depicted in the left
column of panels. This means that some athletes might not be at risk
for detection based on the ABP despite using rHuEPO. Moreover, in
practice, sensitivity of the ABP might fall due to potential lower doses
1300 HEUBERGER ET AL.being used (micro‐dosing) and less optimal timing of blood samples as
the anti‐doping organization does not have the information on dosing
times. Other studies evaluating the performance of the ABP showed
somewhat ambiguous findings. One study used approximately half
the weekly dose of our study after a high dose period of 250 IU/kg
three times a week and found 100% subjects to have at least one sus-
picious or abnormal measurement.25 This difference with our findings
could be due to the very high starting dose used. Additionally, this
study did not investigate evaluator determination based on the ABP,
but only whether individual values were outside the ABP reference
ranges. Also remarkable is that a second, unblinded, study using doses
building up to a similar dose to our weekly dose, found no measure-
ments during the study being flagged as abnormal.26 This study used
99.9% likelihood ranges and did not investigate evaluator determina-
tion based on the ABP. Our own model used similar limits (99.7%) indi-
cating the fact that an evaluator interpreted the ABP in our study
might give more insight into the observed pattern.7.4 | Limitations
There are several limitations to our study. First, although unlikely, it
cannot be ruled out that placebo‐treated subjects administered
rHuEPO outside the proceedings of the study. Given that false pre-
sumptive findings were distributed over many subjects, this seems
an unlikely explanation for these observations.
Second, for reasons of restrictions in time and personnel, confirma-
tion analysis was not performed for isoelectric focusing, and only for a
selection of 14 samples, including all false presumptive findings, for
sarcosyl‐PAGE. In this respect, our study design did not follow regular
anti‐doping procedures to forward all screening positive samples to a
confirmation analysis, nor did it perform a third (B‐sample) analysis
or solicit a second opinion by an expert. As the confirmation analysis
only included a limited number of samples, the characteristics of this
confirmation analysis by itself, including the false positive rate, is
somewhat uncertain.
Furthermore, most subjects received higher doses (8000 or 10
000 IU) at the last dose and the accompanying urine samples taken
more than 10 days after dosing, than at the second dose (5000 IU),
which could have impacted the urine assay results over time. But even
with a higher dose sensitivity was well below 40% for these samples.
Additionally, it is not possible to verify if sample swapping in the prep-
aration or re‐labeling of samples occurred, which might be an alterna-
tive explanation to the discrepancy observed for several samples
between results for screening and confirmation analysis. However,
this seems unlikely as the screening assay, which showed false pre-
sumptive findings, used the standard sample preparation procedure
as for official doping samples. Moreover, such events would then also
contribute to overall assay performance in the official WADA proce-
dure. The re‐labeling procedure performed here between the screen-
ing and confirmation analysis is not part of the official WADA
procedure, but was also performed by double‐checking by two staff
members. Finally, observed characteristics for the assays apply tothe materials and methods used here. Deviations, such as applying a
1.0 mm gel in contrast to the 1.5 mm gel used in this study (as based
on a previous publication18), might change the assay performance to
some extent.
For the ABP, a limitation was that samples were analyzed on a dif-
ferent type of analyzer, although from the same manufacturer, than
the Sysmex XT 2000i that is used by anti‐doping laboratories. In addi-
tion, the ABP algorithm used by WADA was not available to us, and so
the current method was an approximation of the official procedure.
Nevertheless, these discrepancies should not have a major impact on
the ABP profiles and so the outcome of the review of the ABPs, we
feel, can be considered indicative of the first stage of ABP perfor-
mance at the APMU.
Information about factors that might influence markers in the ABP
(eg, altitude training) would be available for the evaluator assessment.
This information was not systematically recorded in the present study,
and although no such events were reported by subjects, occurrence
could have impacted ABP review. It should also be noted that the rel-
atively high sampling frequency applied in this study, with intervals of
as short as two weeks, could lead to the individual reference ranges
moving along with the observed values more than with longer inter-
vals and thereby reducing the chance values to fall outside the range.
The selected window is however the smallest acceptable window
according to the ABP and so these data should still be correctly inter-
pretable. Finally, in the WADA setting, after assessment of an ABP by
an APMU, suspicious ABPs will be sent for review to a WADA hema-
tology expert. If this expert confirms the suspicious finding, they and
two other experts will determine, based on all available information
and possibly additional requested information, whether the profile is
indeed indicative of blood doping. For this study, several WADA
hematology experts were approached to participate in assessment of
the ABPs of this study, but all of them declined. Therefore, the results
reported here can only be considered to resemble the first part of the
official system. But as only suspicious results are forwarded to the
expert, ABP sensitivity would at best stay at the same level.8 | CONCLUSION
The sarcosyl‐PAGE urine assay for rHuEPO (specifically epoetin β) did
not show false positive results after confirmation analysis, but it does
have shortcomings such as a limited detection window. In addition, it
is of some concern that in this study we observed a higher rate of
non‐detectable samples in subjects treated with rHuEPO. Adding a
control internal standard to each sample and measuring total erythro-
poietin levels using an immunoassay could address the latter issue.
The IEF assay in our study was inferior to the sarcosyl‐PAGE assay.
The ABP had a much higher sensitivity than the assays using a single
urine sample, although it too did not classify all passports correctly.
In summary, we showed that all three methods evaluated in this study
have their shortcomings and challenges and that it is critical to con-
tinue research to improve existing and develop new doping detection
methods.
HEUBERGER ET AL. 1301KEY FINDINGS
World Anti‐Doping Agency methods for detection of recombinant
human erythropoietin were evaluated in trained cyclists. Detection
in urine by sarcosyl‐PAGE had a sensitivity of 63.8% and isoelectric
focusing of 58.6%, with a peak in sensitivity between 2 and 6 days
after dosing, rapidly dropping outside this window. False presumptive
finding rates were 4.3% and 6%, respectively, but none of the false
presumptive findings tested positive in the confirmation analysis. Sen-
sitivity of the athlete biological passport that integrates longitudinal
hematological data was 91.3%.
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